Advertisement
Advertisement
U.S. markets close in 1 hour 35 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Greenwich LifeSciences, Inc. (GLSI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
31.10-0.33 (-1.05%)
As of 02:22PM EST. Market open.
Advertisement
Sign in to post a message.
  • R
    Real Immuno Investor 10
    $CNTX conversation
    Board PSA - $SLS short lowlife tagged cntx attempting to lure sls buyers here. Even though Her2+ are not being tested. That is what $GLSI and $SLS agents treat. Her2+ only. SLS has IMMINENT trial data virtually identical to what Launched $GLSI 2,500% in one day last year. The same docs are running the sls trial, same patient setting, same herceptin combo and the doctors have said NPs is more effective than the GLSI Drug.
    Check my previous posts for DD confirmation - SLS is now on the Launch pad
    Bullish
  • S
    Scamster_CEO_Exposer
    $SLS conversation
    @real: r u following cntx? looks like bettering $glsi, presentation dec7-10th. by the time, your $sls ceo wakes up, someone else could have walked away with the laurels, trophy and the investors… what can we tell a guy who says ‘soon’=‘>3months’. huh!
  • R
    Real Immuno Investor 10
    $SLS conversation
    $SLS Dr. Mittendorf and Dr. Peoples are saying Nps is as Good As or better than $GLSI 's drug GP2. --> GLSI launched 2,600% in a single day based on their Trial Data - NPS RESULTS R NOW IMMINENT
    "Trastuzumab increased the sensitivity of the tumor cells to CTL-mediated lysis after stimulation with either nelipepimut-S or GP2, even in patients with low levels of HER2 expression. Interestingly, they also found peripheral blood lymphocytes lyse trastuzumab-treated breast cancer cells more efficiently after nelipepimut-S vaccination. We are currently investigating the possibility of a synergistic immunologic effect when nelipepimut-S is given in combination with trastuzumab in a phase II trial in HER2 over-expressing (3+ by IHC; NCT02297698).’"
    Bullish
  • M
    Matthew
    Test of patience, one more weeks guys, rebound would be huge
  • R
    Real Immuno Investor 10
    $SLS conversation
    Dmented is Scared Nps ~ Phase 2B Herceptin results for HER2 BC now imminent. Another success like Nps + Herceptin for TNBC or a result like $Glsi could double or triple the share price instantly - when it hits.
    Nct site updated Nov 16 - something is about to happen. Ceo in Aug, “Stay tuned for a Nps Announcement “ and “its $roche” in June
    Herceptin is ineffective In TNBc sans Nps https://ascopubs.org/doi/10.1200/JCO.2019.37.8_suppl.1
    Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus

    Also, Two Binary readouts in January. Gps+Keytruda Ovarian results , the additional 6 months time will confirm OS better than soc of 9-12months, remeber ALL GPS/key patients were alive at the 9 months mark.
    1 Background: Preclinical data shows synergism between trastuzumab (Tz) and HER2-targeted vaccines. We evaluated adjvuant nelipepimut-S (NPS) + GM-CSF with Tz compared to Tz with GM-CSF alone in HER2 low-expressing (LE) breast cancer (BC) patients (p
    1 Background: Preclinical data shows synergism between trastuzumab (Tz) and HER2-targeted vaccines. We evaluated adjvuant nelipepimut-S (NPS) + GM-CSF with Tz compared to Tz with GM-CSF alone in HER2 low-expressing (LE) breast cancer (BC) patients (p
    ascopubs.org
  • R
    Real Immuno Investor 10
    $SLS conversation
    Dmented is Scared of Nps ~ Phase 2B Herceptin results for HER2 BC now imminent. Another success like Nps + Herceptin for TNBC or a result like $Glsi could double or triple the share price instantly - Imminent NCT site updated Nov 16 - something is about to happen. Ceo in Aug, “Stay tuned for a Nps Announcement “ and “its $roche” in June
    Herceptin is ineffective In TNBc sans Nps https://ascopubs.org/doi/10.1200/JCO.2019.37.8_suppl.1
    Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus

    Also, Two Binary readouts in January. Gps+Keytruda Ovarian results , the additional 6 months time will confirm OS better than soc of 9-12months, remeber ALL GPS/key patients were alive at the 9 months mark.
    1 Background: Preclinical data shows synergism between trastuzumab (Tz) and HER2-targeted vaccines. We evaluated adjvuant nelipepimut-S (NPS) + GM-CSF with Tz compared to Tz with GM-CSF alone in HER2 low-expressing (LE) breast cancer (BC) patients (p
    1 Background: Preclinical data shows synergism between trastuzumab (Tz) and HER2-targeted vaccines. We evaluated adjvuant nelipepimut-S (NPS) + GM-CSF with Tz compared to Tz with GM-CSF alone in HER2 low-expressing (LE) breast cancer (BC) patients (p
    ascopubs.org
  • R
    Real Immuno Investor 10
    $SLS conversation
    Dr. Mittendorf, Dr. Peoples are saying Nps is as Good As or better than $GLSI 's drug GP2. --> GLSI launched 2,600% in a single day based on their Trial Data - NPS RESULTS R NOW IMMINENT
    "Trastuzumab increased the sensitivity of the tumor cells to CTL-mediated lysis after stimulation with either nelipepimut-S or GP2, even in patients with low levels of HER2 expression. Interestingly, they also found peripheral blood lymphocytes lyse trastuzumab-treated breast cancer cells more efficiently after nelipepimut-S vaccination. We are currently investigating the possibility of a synergistic immunologic effect when nelipepimut-S is given in combination with trastuzumab in a phase II trial in HER2 over-expressing (3+ by IHC; NCT02297698).’"
    Bullish
  • S
    Scamster_CEO_Exposer
    $SLS conversation
    would be interesting to see immuno/dude/jim reaction when stock doesn’t go up next week as they seem to be touting: nov19 date and nps sale. we can bank on the snail pace of this company: world moves in days, this one in decades… no approval till 2024 or 2025… ceo will just delay, dilute, drag and repeat forever. his devotees here will keep pumping in the meantime.

    Jason Mccarthy said 13.5+ target last year. here we are after 10+ months just only close to half his PT… of course, he did not account for the ceo’s style of functioning: delay-dilute-disappoint/drag_on_without_updates…

    those of you waiting for $glsi type increase: fyi, glsi has a more trustworthy ceo and market sentiment is much better compared to sls (thanks to Angelos)
  • E
    Ez$
    $SLS conversation
    Something Big is about to Hit - Nov 19 In June's Corp update the Ceo was asked about NPS by all three analysts in the q&A. Each one, asked about it, interesting considering the Market seems not to Give Nps any value, though $GLSI Is worth $500. Nps Licensing was Jason McCarthys first question and the last analyst said something about the great potential with bio similars and so on and then the ceo cut him of and said " NO it's ROCHE. " Like it was a Done Deal. DID anyone else catch that???
    Combines w the settlement and also the Aug commentary where he went out of his way to say there "would be an announcement very soon".

    I expect news: Nps combined wHerceptin reduced TNBC by 80%, in a phase 2b. Something Big Is About hit.
    Bullish
  • R
    Real Immuno Investor 10
    $SLS conversation
    Price will be much higher when this is released-Imminent December Trial Results. Identical Trial parameters to the $GLSI Herceptin combo trial that added over a billion in Market value in one day. Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients. Study Start Date : October 2014 Completion Date : December 2021
    https://www.bloombergquint.com/business/tiny-biotech-s-wild-ride-extends-as-day-traders-chase-998-boom
    Bullish
  • R
    Real Immuno Investor 10
    $SLS conversation
    December Trial Results. Identical Trial parameters to the $GLSI Herceptin combo trial that added over a billion in Market value in one day. Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients. Study Start Date : October 2014 Completion Date : December 2021
    https://www.bloombergquint.com/business/tiny-biotech-s-wild-ride-extends-as-day-traders-chase-998-boom
    Greenwich LifeSciences Inc., the biotech firm that soared 998% on Wednesday, is flying high as day.
    Greenwich LifeSciences Inc., the biotech firm that soared 998% on Wednesday, is flying high as day.
    www.bloombergquint.com
  • E
    Ez$
    $SLS conversation
    While all the conman beg for us to Sell them our shares keep in Mind it is only a Matter of time for the Phase 3 data - 7 ish months for 1,000's of Percent Gain. My Est is a $3B Market Cap at that time. $7’s gonna be $70 and then $170 in less than 7 months time - Aml P3 Priceless Gps $MRK $BMY Trial Results 5/6 weeks, Nps $Rhhby $Glsi type results due Now, Litigation Finalized, Today, Licensing cleared and Imminent - Lots of Action for this low float baby bio coming in Nov, Dec, and January
    Bullish
  • g
    greg
    $SLS conversation
    $SLS Has an Identical Trial the $GLSI trial, It will report Results Imminently.
    Greenwhich Life Sciences rockets 2,941% in a Single Day after reporting Phase 2 data on Breast Cancer Treatment Matthew Fox Dec 9 2020 Greenwich LifeSciences skyrocketed as much as 2,941% on Wednesday following encouraging phase 2b data for its breast cancer immunotherapy treatment, GP2.
    A poster presentation for GP2 at the San Antonio Breast Cancer Symposium revealed a 100% survival rate for all participants in its phase 2b clinical trial.
    Greenwich LifeSciences is now preparing to enter GP2 into a phase 3 clinical trial to treat a similar population of moderate to severe breast cancer patients.

    Investors had a field day with Greenwich LifeSciences on Wednesday after the tiny biotech company skyrocketed as much as 2,941% on encouraging phase 2b data for its breast cancer immunotherapy treatment, GP2.
    On Tuesday, shares of Greenwich LifeSciences closed at $5.20. The stock proceeded to trade as high as $158.07 just before 3 p.m. on Wednesday. The market value of Greenwich soared to more than $1.5 billion at intraday highs, up from just $62 million the prior day.
    The stock was halted nearly 20 times throughout Wednesday's trading session due to heightened volatility.
    Investors were clearly impressed with phase 2b data for Greenwich LifeScience's GP2, which was revealed in a poster presentation at the San Antonio Breast Cancer Symposium.
  • E
    Ez$
    $SLS conversation
    Something Big is about to Hit - Nov 19 In June's Corp update the Ceo was asked about NPS by all three analysts in the q&A. Each one, asked about it, interesting considering the Market seems not to Give Nps any value, though $GLSI Is worth $500. Nps Licensing was Jason McCarthys first question and the last analyst said something about the great potential with bio similars and so on and then the ceo cut him of and said " NO it's ROCHE. " Like it was a Done Deal. DID anyone else catch that???
    Combines w the settlement and also the Aug commentary where he went out of his way to say there "would be an announcement very soon".

    I expect news: Nps combined wHerceptin reduced TNBC by 80%, in a phase 2b. Something Big Is About hit.
    Bullish
  • R
    Real Immuno Investor 10
    $SLS conversation
    Results Imminent NCI Site Updated- This is an Identical Trial to $GLSI that added 1B in Market cap in 1 day Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+) Last Update Posted : November 16, 2021
    ClinicalTrials.gov Identifier: NCT02297698
    Recruitment Status : Active, not recruiting
    First Posted : November 21, 2014
    Last Update Posted : November 16, 2021
    Bullish
  • A
    Anthony
    Loading the boat..... Boat nearly full.... 25k shares!!!
    Bullish
  • E
    Ez$
    $SLS conversation
    While all the conman beg for us to Sell them our shares keep in Mind it is only a Matter of time for the Phase 3 data - 7 ish months for 1,000's of Percent Gain. My Est is a $3B Market Cap at that time. $7’s gonna be $70 and then $170 in less than 7 months time - Aml P3 Priceless Gps $MRK $BMY Trial Results 5/6 weeks, Nps $Rhhby $Glsi type results due Now, Litigation Finalized, Today, Licensing cleared and Imminent - Lots of Action for this low float baby bio coming in Nov, Dec, and January
    Bullish
  • g
    greg
    $SLS conversation
    Any Share Price predictions when this is published? Study completion date: December 2021 Results Imminent NCI Site Updated- This is an Identical Trial to $GLSI that added 1B in Market cap in 1 day Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+) Last Update Posted : November 16, 2021
    ClinicalTrials.gov Identifier: NCT02297698
    Recruitment Status : Active, not recruiting
    First Posted : November 21, 2014
    Last Update Posted : November 16, 2021
    Bullish
  • E
    Ez$
    $SLS conversation
    $7’s gonna be $70 and then $170 in less than 7 months time - Aml P3 Priceless Gps $MRK $BMY Trial Results 5/6 weeks, Nps $Rhhby $Glsi type results due Now, Litigation Finalized, Today, Licensing cleared and Imminent - Lots of Action for this low float baby bio coming in Nov, Dec, and January
    Bullish
  • g
    greg
    $SLS conversation
    Ceo not drawing down on the ATM might mean he knows some valuable news is about to Hit 1. Litigation Finalized Friday Licensing cleared and Imminent* 2. Nps $RHHBY $GLSI type Trial results 4 weeks
    3. and 4. Gps $MRK $BMY Combination Trial Results in 6 weeks Survival surpassing all other treatment options for Ovarian Cancer
    *no partner wants NPs if there are still legal entanglements (anyone who doubts this ask an attny friend)
    - Lots of Action to Rocket the Price Per share coming in Nov, Dec, and January
    Bullish
Advertisement
Advertisement